Cover ImageSALE
Market Research Report

Global Hepatitis Drugs Market 2015-2019

Published by TechNavio (Infiniti Research Ltd.) Product code 346664
Published Content info 118 Pages
Immediate Delivery Available
Price
Back to Top
Global Hepatitis Drugs Market 2015-2019
Published: December 9, 2015 Content info: 118 Pages
Description

About hepatitis

Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases. The viruses that cause hepatitis are of several types: A, B, C, D, E, and G. The most common type of hepatitis viruses are A, B, and C. Hepatitis viruses can cause either acute or chronic infections.

Technavio's analysts forecast the global hepatitis drugs market to grow at a CAGR of 17.1% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global hepatitis drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hepatitis.

Technavio's report, Global Hepatitis Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as the segmentation. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Vertex Pharmaceuticals

Other Prominent Vendors

  • Abbvie
  • Achillion Pharmaceuticals
  • Bristol-Myers Squibb
  • Dynavax Technologies
  • Mitsubishi Tanabe Pharma

Key market driver

  • Emergence of IFN-free therapies
  • For a full, detailed list, view our report

Key market challenge

  • Side-effects of current therapy
  • For a full, detailed list, view our report

Key market trend

  • Collaborations and M&A
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Table of Contents
Product Code: IRTNTR6912

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Product offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Classification
  • Mode of transmission
  • Epidemiology
  • Diagnosis
  • Symptoms
  • Treatment

PART 06: Key marketed drugs

  • Hepatitis A
  • Hepatitis B
  • Hepatitis C

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by type

  • Hepatitis A
  • Hepatitis B
  • Hepatitis C

PART 09: Market segmentation by MOA

  • Virus-specific agents
  • Non-specific agents

PART 10: Geographical segmentation

PART 11: Market drivers

PART 12: Impact of drivers

PART 13: Market challenges

PART 14: Impact of drivers and challenges

PART 15: Market trends

PART 16: Vendor landscape

  • Competitive scenario
  • Gilead Sciences
  • Johnson & Johnson
  • F. Hoffman-La Roche
  • Merck
  • GlaxoSmithKline
  • Vertex Pharmaceuticals
  • Novartis
  • Other prominent vendors

PART 17: Key vendor analysis

  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Roche
  • Vertex Pharmaceuticals

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Mode of transmission and incubation period of different types of hepatitis
  • Exhibit 02: Risk factors for hepatitis A transmission
  • Exhibit 03: Risk factors for hepatitis B transmission
  • Exhibit 04: Risk factors for hepatitis C transmission
  • Exhibit 05: Worldwide endemicity of HAV infection
  • Exhibit 06: Endemicity pattern of HBV worldwide
  • Exhibit 07: Prevalence of HBV in APAC
  • Exhibit 08: Acute hepatitis B infection by age group 2005-2013
  • Exhibit 09: Prevalence of hepatitis B in US 2005-2013
  • Exhibit 10: Estimated HBV incidence rates in APAC countries 2004
  • Exhibit 11: Prevalence rates of hepatitis C across different regions 2012
  • Exhibit 12: Antibodies indicating different hepatitis types
  • Exhibit 13: Tests for viral proteins and generic materials
  • Exhibit 14: Screening tests for hepatitis B infection
  • Exhibit 15: Screening tests for hepatitis C infection
  • Exhibit 16: Types of hepatitis and symptoms
  • Exhibit 17: Recommended dosages and schedules for hepatitis A vaccines
  • Exhibit 18: Recommended dosages and schedules for hepatitis B vaccines
  • Exhibit 19: Combination vaccines for hepatitis A and/or hepatitis B
  • Exhibit 20: Hepatitis A: Key marketed vaccines
  • Exhibit 21: Hepatitis B: Key marketed drugs
  • Exhibit 22: Hepatitis C: Key marketed drugs
  • Exhibit 23: Global hepatitis drugs market 2014-2019 ($ billions)
  • Exhibit 24: Five forces analysis
  • Exhibit 25: Market segmentation by type
  • Exhibit 26: Global hepatitis A drugs market 2014-2019 ($ billions)
  • Exhibit 27: Global hepatitis B drugs market 2014-2019 ($ billions)
  • Exhibit 28: Global hepatitis C drugs market 2014-2019 ($ billions)
  • Exhibit 29: Snapshot of global hepatitis drugs market
  • Exhibit 30: Classification of global hepatitis drugs market by MOA
  • Exhibit 31: Global hepatitis drugs market by geographical segmentation 2014
  • Exhibit 32: List of key drivers
  • Exhibit 33: List of key challenges
  • Exhibit 34: Impact of drivers and challenges
  • Exhibit 35: List of key trends
  • Exhibit 36: Gilead: Pipeline candidates for hepatitis B
  • Exhibit 37: Gilead Sciences: Pipeline candidates for hepatitis C
  • Exhibit 38: Gilead Sciences: Key takeaways
  • Exhibit 39: Johnson & Johnson: Global YoY revenue of Incivo 2012-2014 ($ millions)
  • Exhibit 40: Johnson & Johnson: Global revenue of Olysio 2014 ($ millions)
  • Exhibit 41: Johnson & Johnson: Key takeaways
  • Exhibit 42: Roche: Pipeline candidates for hepatitis C
  • Exhibit 43: F. Hoffman-La Roche: Key takeaways
  • Exhibit 44: Merck: Global YoY revenue of Victrelis 2011-2013 ($ millions)
  • Exhibit 45: Merck: Pipeline candidates for hepatitis C
  • Exhibit 46: Merck: Key takeaways
  • Exhibit 47: GlaxoSmithKline: Pipeline candidates for hepatitis B
  • Exhibit 48: GlaxoSmithKline: Pipeline candidates for hepatitis C
  • Exhibit 49: GlaxoSmithKline: Key takeaways
  • Exhibit 50: Vertex Pharmaceuticals: Global YoY revenue of Incivek 2011-2013 ($ millions)
  • Exhibit 51: Vertex Pharmaceuticals: Pipeline candidates for hepatitis C
  • Exhibit 52: Vertex Pharmaceuticals: Key takeaways
  • Exhibit 53: Novartis: Key takeaways
  • Exhibit 54: Gilead Sciences: List of key drugs
  • Exhibit 55: GlaxoSmithKline: Segmentation by product 2014
  • Exhibit 56: GlaxoSmithKline: Geographical segmentation by revenue 2014
  • Exhibit 57: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 58: Johnson & Johnson: Business segmentation
  • Exhibit 59: Johnson & Johnson: Key products of medical devices segment
  • Exhibit 60: Johnson & Johnson: Medical devices segmentation by revenue 2014
  • Exhibit 61: Merck: Business segmentation
  • Exhibit 62: Merck: Geographical segmentation
  • Exhibit 63: Business segmentation by revenue
  • Exhibit 64: Novartis: Business segmentation
  • Exhibit 65: Novartis: Geographical segmentation
  • Exhibit 66: Novartis: Business segmentation by revenue
  • Exhibit 67: Roche: Business segments
  • Exhibit 68: Roche: Pharmaceuticals segmentation
  • Exhibit 69: Roche: Revenue comparison by business segment
  • Exhibit 70: Roche: Geographical segmentation
  • Exhibit 71: Vertex Pharmaceuticals: Product segmentation by revenue
  • Exhibit 72: Vertex Pharmaceuticals: Product segmentation by revenue 2013 and 2014 ($ millions)
  • Exhibit 73: Vertex Pharmaceuticals: Geographical segmentation
Back to Top